Company intelligence / Profile preview
Verseon International
California, United Statesverseon.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Verseon's lead candidate VE-1902, a thrombin inhibitor for cardiovascular disorders, is in Phase 1. Additional programs address diabetic vision loss (IND-prep), multidrug-resistant cancer (preclinical), solid-tumor metastasis (optimization), and CD73-positive cancer (preclinical). Clinical data for efficacy/safety is not yet publicly detailed.
- Therapeutic areas
- OncologyCardiovascularOphthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Verseon International.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verseon International.